Table 1 Spirometry in Normal & Asthmatic Subjects (Mean ± SD)
From: The pulmonary effects of intravenous adenosine in asthmatic subjects
| Â | Normals | Asthmatics | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Placebo | Adenosine | Placebo | Adenosine | ||||||||
| Â | Baseline | Post | p | Baseline | Post | p | Baseline | Post | p | Baseline | Post | p |
FEV1, L | 3.63 ± 0.49 | 3.61 ± 0.51 | ns | 3.63 ± 0.56 | 3.67 ± 0.59 | ns | 2.66 ± 0.75 | 2.61 ± 0.85 | ns | 2.68 ± 0.78 | 2.71 ± 0.84 | ns |
FVC, L | 4.53 ± 0.65 | 4.48 ± 0.60 | ns | 4.47 ± 0.71 | 4.50 ± 0.72 | ns | 4.09 ± 0.88 | 4.02 ± 1.00 | ns | 4.09 ± 1.00 | 4.10 ± 1.00 | ns |
FEV1/FVC,% | 80.0 ± 3.0 | 80.3 ± 3.4 | ns | 81.5 ± 3.6 | 83.5 ± 2.4 | ns | 65.3 ± 12.9 | 65.2 ± 14.5 | ns | 66.0 ± 12.7 | 55.0 ± 12.9 | ns |